Setup

CVRx ($CVRX, $199M market cap) makes Barostim, a neuromodulation implant for heart failure. The stock dropped 64% over the past year on decelerating revenue growth (+4% YoY in Q4 2025) and cash burn concerns. Today's 8-K filing disclosed preliminary Q1 2026 results that contradict the bear thesis: revenue re-accelerated to +20% YoY, and the company quantified for the first time that its new CPT Category I codes are improving prior authorization approval rates.

What the filing says

Three numbers matter from the 8-K (Item 2.02, Exhibit 99.1):

Revenue: $14.7-14.8M, +20% YoY. Q1 2025 was $12.3M. Top of the $13.7-14.7M guidance range. The prior quarter grew 4%. The growth rate quintupled in one quarter.

Prior authorization approvals: 31% to 50%. Medicare Advantage 30-day approval rate (managed by CVRx's in-house team) went from 31% in 2024 to 44% in 2025 to 50% in January-February 2026. The +6pp step-change in two months post-CPT-code-effective-date is the first quantified evidence that the Category I transition (from Category III, effective January 1, 2026) is reducing prior auth friction. This is the leading indicator -- 50% means half of MA cases still get denied, but the trajectory is what matters.

Gross margin: 87%. Above the 84-86% full-year guidance, up 300bps YoY. Revenue grew 20% while OpEx grew 5.5%. Operating leverage is emerging.

One yellow flag: cash at March 31 was $72.3M, implying ≈$13.4M burn in Q1 versus guided pace of $7.5-8.75M per quarter ($30-35M full year). Q1 ran nearly 2x guidance. Possible explanations include BENEFIT-HF trial site activation costs (first site went live March 31) and seasonal front-loading. The May 14 earnings call needs to address this.

What the market thinks

At $7.69, CVRX trades at 2.9x EV/FY2026 guided revenue. Reverse-engineering implied probabilities across three scenarios -- sustained re-acceleration ($13 target), moderate growth ($9), and thesis failure ($4) -- the market assigns roughly 20-25% to accelerates and 40-45% to fizzles.

We assign 50% to accelerates and 15% to fizzles. The gap is 25-30pp on the key state, depending on assumptions about scenario targets. Options are too illiquid (≈1,500 total OI) to sharpen this.

Variance decomposition provides context: 94.7% of CVRX's return variance is idiosyncratic, with market beta at 4.4% and sector/style at 0.9%. CPT adoption drives 55-60% of the idiosyncratic variance directly, plus another 10-12% indirectly through cash/survival correlation. This is a single-factor thesis on a single-product company.

Why the gap exists

The data is hours old. The 8-K was filed today. At $199M market cap with 7 covering analysts, information diffusion is slow. The stock is up 7.5% on 0.6x average volume -- partial, not full, repricing.

The mechanism proof is buried. The headline is revenue. The prior auth approval data -- 31% to 50%, the specific quantification that CPT codes are reducing friction -- is in the body of the press release. Screens won't flag it.

9.2% short interest is stale. Shorts are positioned for the Q4 deceleration story. Days to cover is 3.9.

Three cross-ticker data points corroborate the mechanism but haven't been connected. (1) VMD (Viemed Healthcare, respiratory DME) reported January 2026 was "one of strongest new ventilator setup months in history" after CMS replaced subjective MA criteria with objective NCD standards -- the same Cat III-to-Cat I dynamic as CVRX. (2) NRXS, which got CPT Category I codes on the same January 1 effective date, confirmed that codes alone are insufficient without written payer medical policy -- CVRX's faster inflection tracks their 252 active centers and in-house prior auth team, an infrastructure advantage NRXS lacks. (3) CVRX's Barostim CPT codes (64654, 64655) are not on the CMS WISER targeted code list, while competitors INSP and LIVN are seeing AI-powered prior auth denials in 6 pilot states.

Risks (ranked by impact)

1. Q1 was pent-up demand. CPT codes took effect January 1. Some Q1 volume may reflect procedures delayed in Q4 while billing teams prepared for new coding. If Q2 revenue falls to $15M or below, the re-acceleration was a one-off. Probability: 15-20%.

2. Cash burn is structural. $13.4M in Q1 vs $8M/quarter guidance. If this pace continues, annual burn is $54M on $72M cash -- 1.3 years of runway. The $50M ATM facility at $7.69 means ≈6.6M new shares, ≈25% dilution. If management can't explain the overshoot on May 14, fizzles probability increases.

3. Single-product concentration. One product, one therapy, one reimbursement code set. No fallback if anything goes wrong. BENEFIT-HF trial is 5-7 years from readout.

4. Insider absence. J&J (beneficial owner) steadily selling. No company insiders buying in the open market at current prices. Not disqualifying in isolation -- small-cap medtech officers rarely buy -- but no one with inside information is backing the thesis with personal capital.

Catalysts (with dates)

May 14, 2026: Q1 earnings call. Cash burn explanation, potential guidance raise (P ≈30%). The next decision point.

Mid-May 2026: SRTS Q1 results. Direct CPT comp (skin cancer devices, same effective date). If SRTS also inflects, it corroborates the mechanism as generalizable. If SRTS disappoints, CVRX's result is infrastructure-specific.

August 2026: Q2 results. Q2 revenue above $16.5M confirms the re-acceleration is durable. Below $15M, the market reprices to fizzles.

What would change our mind

MA prior auth approval rate stalls at 50%. Revenue re-acceleration requires the approval rate to keep climbing. The trajectory -- 31% to 44% to 50% -- is the leading indicator. If the next disclosure shows no improvement, the CPT code benefit has plateaued at an approval rate that still rejects half of Medicare Advantage cases. VCEL achieves >95% on mature products. If 50% is the ceiling for Barostim, growth decelerates back to 15% or below.

A major commercial payer issues a non-coverage determination. NRXS learned that CPT codes alone don't guarantee coverage -- each payer must adopt written medical policy. The MA approval data is encouraging, but we don't know commercial payer rates. A large payer explicitly declining to cover Barostim under Cat I codes would cap the addressable market in a way that makes the bear case more likely than the market's 40-45%.

Insider buying at SRTS or NRXS but not CVRX. If peer companies with the same CPT dynamic see management buying stock while CVRX's leadership continues selling post-award shares, it suggests the signal is weaker for CVRX than the comparable set.

Evidence